Jan 06, 2016
Chugai and Novartis Pharma to Terminate Co-Marketing Agreement of Aromatase Inhibitor “Femara® Tablets 2.5 mg,” a Treatment for Breast Cancer after Menopause
TOKYO, January 6, 2016 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor “Femara® tablets 2.5 mg” (generic name: letrozole, hereafter Femara®), a treatment for breast cancer after menopause in Japan, as of January 31, 2016.
Novartis Pharma will be solely responsible for the distribution and commercialization of Femara® in Japan from February 1, 2016.
Chugai and Novartis Pharma will cooperate to accomplish a smooth transition. During the transition period, both companies will maintain the same level of product supply and adequate commercial activities to satisfy any medical needs.
About Femara® Tablets 2.5 mg
| Generic Name: | Letrozole |
|---|---|
| Brand Name: | Femara® Tablets 2.5 mg |
| Approval Date: | January 23, 2006 |
| Launch Date: | May 11, 2006 |
| Indication: | Breast cancer after menopause |
| Dosage and administration: | The usual adult dosage is 2.5 mg administered orally once daily. |
| Drug Price: | JPY 674.1/Tablet |
| Manufacturer & Distributor: | Novartis Pharma K.K. |
| Distribution and commercialization: | Novartis Pharma K.K. (on or after February 1, 2016) |
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Koki Harada
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
